The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria - PubMed
3 hours ago
- #antimalarial drug
- #malaria
- #clinical trial
- MMV367, a pyrrolidinamide, rapidly clears Plasmodium falciparum in healthy adults with experimental malaria.
- Doses ≥20 mg resulted in a parasite clearance half-life of 2.2 to 4.3 hours and elimination half-life of 1.1 to 2.7 hours.
- MMV367 targets P. falciparum acyl-CoA synthetases 10 and 11, interfering with parasite metabolism.
- Model-derived efficacy parameters included a minimum inhibitory concentration of 6.3 ng/ml and minimum parasiticidal concentration of 54 ng/ml.
- No resistance to MMV367 was observed in vitro, and adverse events were mild and not dose-related, supporting further clinical development.